Small molecule Z363 co‐regulates TAF10 and MYC via the E3 ligase TRIP12 to suppress tumour growth
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Yan Xiong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Life Sciences, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Neoplasms, Ubiquitin-Protein Ligases, Proto-Oncogene Proteins c-myc, TATA-Binding Protein Associated Factors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Background
The MYC oncoprotein, also known as the master regulator of genes, is a transcription factor that regulates numerous physiological processes, including cell cycle control, apoptosis, protein synthesis and cell adhesion, among others. MYC is overexpressed in approximately 70% of human cancers. Given its pervasive role in cancer biology, MYC down‐regulation has become an attractive cancer treatment strategy.
Methods
The CRISPR/Cas9 method was used to produce KO cell models. Western blot was used to analyzed the expressions of MYC and TATA‐binding proteinassociated factors 10 (TAF10) in cancer cells (MCF7, A549, HepG2 cells) Cell culture studies were performed to determine the mechanisms by which small molecules (Z363119456, Z363) affects MYC and TAF10 expressions and functions. Mouse studies were carried out to investigate the impact of Z363 regulation on tumor growth.
Results
Z363 activate Thyroid hormone Receptor‐interacting Protein 12 (TRIP12), which phosphorylates MYC at Thr58, resulting in MYC ubiquitination and degradation and thereby regulating MYC target genes. Importantly, TRIP12 also induces TAF10 degradation, which reduces MYC protein levels. TRIP12, an E3 ligase, controls MYC levels both directly and indirectly by inhibiting MYC or TAF10 activity.
Conclusions
In summary,these results demonstrate the anti‐cancer properties of Z363, a small molecule that is co‐regulated by TAF10 and MYC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Life Sciences, Chongqing University, Chongqing, China.
- Molecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
- Department of Oncology, Faculty of Medicine, Linköping University, Sweden.
- Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Sweden.
- Department of Pathology, Chongqing Hygeia Hospital, Chongqing, China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Xiong, Y., Wang, L., Xu, S., Fu, B., Che, Y., Zaky, M. Y., Tian, R., Yao, R., Guo, D., Sha, Z., Lin, F., Lin, X., & Wu, H. (2023). Small molecule Z363 co‐regulates TAF10 and MYC via the E3 ligase TRIP12 to suppress tumour growth. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1153
Vancouver
Xiong Y, Wang L, Xu S, Fu B, Che Y, Zaky MY, et al. Small molecule Z363 co‐regulates TAF10 and MYC via the E3 ligase TRIP12 to suppress tumour growth. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1153
BibTeX
@article{Xiong2023,
author = {Xiong, Yan and Wang, Lulu and Xu, Shiyao and Fu, Beibei and Che, Yuchen and Zaky, Mohamed Y and Tian, Rong and Yao, Rui and Guo, Dong and Sha, Zhou and Lin, Feng and Lin, Xiaoyuan and Wu, Haibo},
title = {Small molecule Z363 co‐regulates TAF10 and MYC via the E3 ligase TRIP12 to suppress tumour growth},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1153}
}
EUVIMED